Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria

J Intern Med. 1994 Jan;235(1):85-9. doi: 10.1111/j.1365-2796.1994.tb01037.x.

Abstract

Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal disorder thought to arise in a multipotent haemopoietic stem cell. A distinct clinical feature is a tendency to thrombosis, with a particular predilection for the hepatic veins (Budd-Chiari syndrome). We report here on two patients with PNH who developed hepatic vein thrombosis (HVT) and who were treated with tissue plasminogen activator (t-PA). Both patients had a marked clinical and radiological improvement following the t-PA treatment and remain well over 2 years and 6 years after the treatment. This method of thrombolysis for HVT occurring in PNH has only been reported in two previous patients with limited follow-up. We suggest that this therapy is a useful first-line treatment for PNH patients who develop HVT.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Budd-Chiari Syndrome / drug therapy*
  • Budd-Chiari Syndrome / etiology
  • Female
  • Hemoglobinuria, Paroxysmal / complications*
  • Humans
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Tissue Plasminogen Activator